Whole-genome sequencing facilitates patient-specific quantitative PCR-based minimal residual disease monitoring in acute lymphoblastic leukaemia, neuroblastoma and Ewing sarcoma

BACKGROUND: Minimal residual disease (MRD) measurement is a cornerstone of contemporary acute lymphoblastic leukaemia (ALL) treatment. The presence of immunoglobulin (Ig) and T cell receptor (TCR) gene recombinations in leukaemic clones allows widespread use of patient-specific, DNA-based MRD assays...

Descripción completa

Detalles Bibliográficos
Autores principales: Subhash, Vinod Vijay, Huang, Libby, Kamili, Alvin, Wong, Marie, Chen, Dan, Venn, Nicola C., Atkinson, Caroline, Mayoh, Chelsea, Venkat, Pooja, Tyrrell, Vanessa, Marshall, Glenn M., Cowley, Mark J., Ekert, Paul G., Norris, Murray D., Haber, Michelle, Henderson, Michelle J., Sutton, Rosemary, Fletcher, Jamie I., Trahair, Toby N.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Nature Publishing Group UK 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810788/
https://www.ncbi.nlm.nih.gov/pubmed/34471258
http://dx.doi.org/10.1038/s41416-021-01538-z

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8810788/
https://www.ncbi.nlm.nih.gov/pubmed/34471258
http://dx.doi.org/10.1038/s41416-021-01538-z

Ejemplares similares